CAN CELL-BASED INNOVATION KEEP HUMANITY IN PEAK CONDITION?

Christian Ekler moderates a discussion on healthcare innovation, with panelists Hans Kirstein, Ying Li, and Alex Savaronkov. Hans, a neuroscience professor turned drug developer, discusses his work on immunomodulators and reversing aging manifestations. Ying, founder of Emma Capital, focuses on AI, digital health, and sustainability, advocating for a holistic approach to health. Alex, CEO of Insilica Medicine, highlights AI's role in drug discovery and the challenges in scaling cell therapies. The panel explores the potential of cell-based innovation, moving from transplantation to models and secretome products. They address the need for harmonized global regulations to prevent fragmentation of access to cell therapies. The discussion shifts to financial models, with Ying suggesting leveraging nature and AI for cost-effective solutions. Alex emphasizes that AI can reduce production costs for cell therapies at every step, from disease modeling to production. Finally, each panelist shares their wish for a future advancement in their respective fields.